Qiagen (QGEN)
Market Price (12/29/2025): $45.69 | Market Cap: $9.9 BilSector: Health Care | Industry: Life Sciences Tools & Services
Qiagen (QGEN)
Market Price (12/29/2025): $45.69Market Cap: $9.9 BilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 26% | Weak multi-year price returns2Y Excs Rtn is -37%, 3Y Excs Rtn is -86% | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -2.1% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 32%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 23% | Key risksQGEN key risks include [1] navigating specific regulatory hurdles such as IVDR, Show more. | |
| Low stock price volatilityVol 12M is 25% | ||
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 26% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 32%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 23% |
| Low stock price volatilityVol 12M is 25% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -37%, 3Y Excs Rtn is -86% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -2.1% |
| Key risksQGEN key risks include [1] navigating specific regulatory hurdles such as IVDR, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
The requested time period from August 31, 2025, to December 29, 2025, is in the future. As such, it is not possible to provide factual reasons for a specific stock movement of -2.4% during this future period. However, based on available future-dated news and analyst expectations leading into and within that period, here are some key developments that could influence Qiagen's stock.
1. QIAGEN's Strong Q2 2025 Performance and Raised Full-Year Outlook.In August 2025, Qiagen reported strong second-quarter results, driven by robust demand for its diagnostic solutions and improved profitability. The company also raised its full-year 2025 sales outlook, with net sales expected to grow 4-5% at constant exchange rates (CER). This positive financial performance could contribute to investor confidence.
2. Q3 2025 Results Exceeding Outlook and Raised FY 2025 Adjusted EPS Target.In November 2025, Qiagen announced its third-quarter 2025 results, exceeding its outlook with net sales of $533 million and adjusted diluted EPS of $0.61. The company reaffirmed its full-year 2025 net sales growth target of 4-5% CER and raised its adjusted diluted EPS target to approximately $2.38 CER. These strong results and increased profitability targets indicate a positive operational trajectory.
Show more
1. QIAGEN's Strong Q2 2025 Performance and Raised Full-Year Outlook.In August 2025, Qiagen reported strong second-quarter results, driven by robust demand for its diagnostic solutions and improved profitability. The company also raised its full-year 2025 sales outlook, with net sales expected to grow 4-5% at constant exchange rates (CER). This positive financial performance could contribute to investor confidence.
2. Q3 2025 Results Exceeding Outlook and Raised FY 2025 Adjusted EPS Target.In November 2025, Qiagen announced its third-quarter 2025 results, exceeding its outlook with net sales of $533 million and adjusted diluted EPS of $0.61. The company reaffirmed its full-year 2025 net sales growth target of 4-5% CER and raised its adjusted diluted EPS target to approximately $2.38 CER. These strong results and increased profitability targets indicate a positive operational trajectory.
Show more
Stock Movement Drivers
Fundamental Drivers
The 3.3% change in QGEN stock from 9/28/2025 to 12/28/2025 was primarily driven by a 7.0% change in the company's Net Income Margin (%).| 9282025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 43.90 | 45.37 | 3.35% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 2040.07 | 2070.78 | 1.51% |
| Net Income Margin (%) | 18.30% | 19.58% | 6.96% |
| P/E Multiple | 25.48 | 24.27 | -4.73% |
| Shares Outstanding (Mil) | 216.70 | 216.87 | -0.08% |
| Cumulative Contribution | 3.35% |
Market Drivers
9/28/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| QGEN | 3.3% | |
| Market (SPY) | 4.3% | 20.5% |
| Sector (XLV) | 15.2% | 54.6% |
Fundamental Drivers
The -4.5% change in QGEN stock from 6/29/2025 to 12/28/2025 was primarily driven by a -78.1% change in the company's P/E Multiple.| 6292025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 47.52 | 45.37 | -4.53% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 2002.87 | 2070.78 | 3.39% |
| Net Income Margin (%) | 4.68% | 19.58% | 318.55% |
| P/E Multiple | 110.78 | 24.27 | -78.09% |
| Shares Outstanding (Mil) | 218.38 | 216.87 | 0.69% |
| Cumulative Contribution | -4.53% |
Market Drivers
6/29/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| QGEN | -4.5% | |
| Market (SPY) | 12.6% | 15.6% |
| Sector (XLV) | 17.0% | 58.0% |
Fundamental Drivers
The 1.4% change in QGEN stock from 12/28/2024 to 12/28/2025 was primarily driven by a 314.2% change in the company's Net Income Margin (%).| 12282024 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 44.75 | 45.37 | 1.38% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1966.17 | 2070.78 | 5.32% |
| Net Income Margin (%) | 4.73% | 19.58% | 314.16% |
| P/E Multiple | 107.05 | 24.27 | -77.33% |
| Shares Outstanding (Mil) | 222.31 | 216.87 | 2.45% |
| Cumulative Contribution | 1.32% |
Market Drivers
12/28/2024 to 12/28/2025| Return | Correlation | |
|---|---|---|
| QGEN | 1.4% | |
| Market (SPY) | 17.0% | 41.0% |
| Sector (XLV) | 13.8% | 59.7% |
Fundamental Drivers
The -6.5% change in QGEN stock from 12/29/2022 to 12/28/2025 was primarily driven by a -7.0% change in the company's Total Revenues ($ Mil).| 12292022 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 48.51 | 45.37 | -6.48% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 2225.93 | 2070.78 | -6.97% |
| Net Income Margin (%) | 20.83% | 19.58% | -6.00% |
| P/E Multiple | 22.48 | 24.27 | 7.98% |
| Shares Outstanding (Mil) | 214.78 | 216.87 | -0.97% |
| Cumulative Contribution | -6.49% |
Market Drivers
12/29/2023 to 12/28/2025| Return | Correlation | |
|---|---|---|
| QGEN | 8.1% | |
| Market (SPY) | 48.4% | 38.6% |
| Sector (XLV) | 17.8% | 56.2% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| QGEN Return | 56% | 5% | -10% | -13% | 6% | 3% | 39% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| QGEN Win Rate | 75% | 50% | 58% | 33% | 58% | 67% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| QGEN Max Drawdown | -2% | -12% | -26% | -29% | -7% | -15% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | QGEN | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -37.4% | -25.4% |
| % Gain to Breakeven | 59.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -15.8% | -33.9% |
| % Gain to Breakeven | 18.8% | 51.3% |
| Time to Breakeven | 83 days | 148 days |
| 2018 Correction | ||
| % Loss | -38.6% | -19.8% |
| % Gain to Breakeven | 62.9% | 24.7% |
| Time to Breakeven | 45 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -45.2% | -56.8% |
| % Gain to Breakeven | 82.4% | 131.3% |
| Time to Breakeven | 532 days | 1,480 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Qiagen's stock fell -37.4% during the 2022 Inflation Shock from a high on 9/2/2021. A -37.4% loss requires a 59.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
AI Analysis | Feedback
Here are 1-2 brief analogies to describe Qiagen:
- Intel for molecular biology labs
- Qualcomm for genetic testing and research
AI Analysis | Feedback
- Sample Preparation Kits & Instruments: Solutions for isolating, stabilizing, and purifying DNA, RNA, and proteins from various biological samples, including both manual kits and automated systems like QIAcube and QIA symphony.
- Molecular Diagnostic Systems (MDx): Integrated platforms and assays for detecting pathogens or biomarkers in clinical samples, exemplified by the QIAstat-Dx system for syndromic testing and QuantiFERON-TB Gold Plus for tuberculosis.
- Next-Generation Sequencing (NGS) Solutions: Comprehensive workflows including library preparation kits, target enrichment panels, and instruments for high-throughput DNA sequencing.
- PCR and Real-Time PCR Assays: Kits and reagents for polymerase chain reaction (PCR) and quantitative real-time PCR, used for gene expression analysis, genotyping, and pathogen detection.
- Bioinformatics Software: Tools and knowledge bases for analyzing, interpreting, and managing genomic and proteomic data generated by their molecular technologies.
AI Analysis | Feedback
Qiagen (QGEN) primarily sells its innovative products and solutions to other companies and institutions globally, rather than directly to individuals. Due to its highly diversified customer base spanning numerous markets and geographies, Qiagen does not typically have individual "major customers" (specific named companies) that account for a significant portion of its revenue (e.g., 10% or more), and as such, these are not disclosed in its public filings. Instead, its customer base can be categorized into the following primary segments:
- Clinical Diagnostics & Healthcare Providers: This category includes hospitals, clinical reference laboratories (e.g., those performing routine or specialized diagnostic tests), and public health institutions. These customers utilize Qiagen's molecular diagnostic solutions for infectious disease testing, oncology, human identification, and other clinical applications. Examples of such entities, though not individually major customers, include large hospital networks and independent diagnostic lab corporations.
- Pharmaceutical & Biotechnology Companies: These customers are involved in drug discovery, development, clinical trials, and manufacturing quality control. They use Qiagen's sample and assay technologies for research and development (R&D) purposes, biomarker discovery, and ensuring the safety and efficacy of their products. This segment includes both large multinational pharmaceutical firms and smaller, innovative biotechnology companies.
- Academic & Research Institutions: This segment comprises universities, government-funded research centers (e.g., those under the National Institutes of Health or similar international bodies), and non-profit research organizations. Researchers within these institutions employ Qiagen's products for fundamental life science research, genomics, proteomics, and other scientific investigations.
AI Analysis | Feedback
null
AI Analysis | Feedback
Thierry Bernard, Chief Executive Officer
Thierry Bernard joined QIAGEN in February 2015 and was named Chief Executive Officer in March 2020 after serving in an interim capacity. Prior to joining QIAGEN, Mr. Bernard spent 15 years at bioMérieux SA, where he held roles of increasing responsibility, including Corporate Vice President, Global Commercial Operations, Investor Relations, and the Greater China Region. He also held senior management positions at several other international companies before bioMérieux. Mr. Bernard has served on the Board of Directors of T2 BioSystems since 2020, was named Chair of the AdvaMedDx Board of Directors in March 2023, and joined the Board of Directors of Neogen Corporation (NASDAQ: NEOG) in 2024. He holds degrees and certifications from institutions including Sciences Po, the London School of Economics, the College of Europe, and Harvard Business School.
Roland Sackers, Chief Financial Officer
Roland Sackers joined QIAGEN in 1999 as Vice President Finance and has served as Chief Financial Officer since 2004. He became a member of the Managing Board in 2006. From 1995 to 1999, Mr. Sackers worked as an auditor with Arthur Andersen Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft. He earned his Masters Degree in Business Administration (Diplom-Kaufmann) from the University of Münster, Germany. Mr. Sackers has been a member of the Supervisory Board and Chairman of the Audit Committee of Evotec SE since 2019. He is also a board member of the industry association BIO Deutschland and previously served as a member of the Supervisory Board and Audit Committee of IBS AG, and on the board of directors of Operon Biotechnologies, Inc.. From 2011 to 2018, he was a non-executive director and chair of the audit committee of Immunodiagnostic Systems Holding PLC (IDS).
Fernando Beils, Senior Vice President, Head of Global Commercial Operations
Fernando Beils is the Senior Vice President, Head of Global Commercial Operations at QIAGEN.
Stephany Foster, Senior Vice President, Head of Human Resources
Stephany Foster is the Senior Vice President, Head of Human Resources at QIAGEN, a role she assumed in October 2019. Before joining QIAGEN in 2005 as Head of Global Internal Audit, she worked in internal audit at Morgan Franklin and Independence Air. Ms. Foster began her career at PricewaterhouseCoopers, specializing in Sarbanes Oxley Auditing. She holds a master's degree in Accounting from the University of Notre Dame and is a Certified Public Accountant (CPA), a Certified Internal and Information Systems Auditor (CIA/CISA), and a Certified Fraud Examiner (CFE).
Antonio Santos, Senior Vice President, Head of Global Operations
Antonio Santos serves as the Senior Vice President, Head of Global Operations for QIAGEN.
AI Analysis | Feedback
Key risks to Qiagen's business include intense competition and rapid technological advancements, fluctuating demand influenced by economic conditions and customer budgets, and operational challenges including regulatory compliance and managing international operations.
- Competition and Rapid Technological Advancements: Qiagen operates in the highly dynamic molecular diagnostics and life science research industry, facing significant competition from both established companies like Roche and Illumina, as well as emerging players, particularly in the Asia-Pacific region. This competitive landscape is constantly reshaped by rapid technological innovations in areas such as next-generation sequencing (NGS), liquid biopsy, and automation. The company must continuously innovate and protect its product differentiation to maintain its market position against rivals.
- Fluctuating Demand and Economic Conditions: Qiagen's business is susceptible to variations in demand for its products, which can be influenced by broader economic conditions, customer budgets, and funding cycles in research and academic markets. For instance, cautious capital spending by some life sciences customers has been observed. Additionally, geopolitical factors like U.S.-China tariffs can impact profitability and create financial headwinds.
- Regulatory and Operational Challenges: The company faces ongoing challenges related to obtaining and maintaining regulatory approvals for its products, such as those required by IVDR. Furthermore, managing international operations, which involves navigating currency fluctuations, diverse regulatory processes, and logistical complexities, presents a continuous risk. Successful integration of acquisitions and adapting products into integrated solutions are also critical operational considerations.
AI Analysis | Feedback
nullAI Analysis | Feedback
Qiagen (symbol: QGEN) operates within several significant addressable markets for its main products and services. The company's total addressable market was estimated at approximately $11 billion in 2024, with a projection to grow to between $13 billion and $14 billion by 2028 globally.
Here's a breakdown of the addressable markets for Qiagen's key offerings:
- Molecular Diagnostics: The global molecular diagnostics market was valued at approximately $14 billion in 2024 and is projected to reach $30.4 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 9% from 2025 to 2033. North America held the largest share of this market, accounting for 40.95% in 2024. Another estimate places the global market at $15.26 billion in 2024, expanding to $21.21 billion by 2032 with a CAGR of 4.2% from 2025-2032.
- PCR Technologies (including QIAcuity Digital PCR, NeuMoDx, QIAstat-Dx): The global PCR technologies market size was approximately $15.78 billion in 2024 and is predicted to increase to $31.39 billion by 2034, with a CAGR of 7.12% from 2025 to 2034. The U.S. market for PCR technologies alone was valued at $5.49 billion in 2024 and is projected to reach $11.10 billion by 2034. More specifically, the global digital PCR (dPCR) market is estimated at $9.39 billion in 2025 and is poised to reach $23.15 billion by 2035, exhibiting a CAGR of 9.4% during the forecast period.
- Next-Generation Sequencing (NGS) Solutions: The global next-generation sequencing market was valued at $9.85 billion in 2024 and is projected to reach $56.04 billion by 2033, demonstrating a substantial CAGR of 21.31% from 2025 to 2033. Another source estimates the global NGS market size at $23.3 billion in 2024, with a projection to reach $85.4 billion by 2033 at a CAGR of 15.5%. North America held the largest market share in NGS in 2024, at over 39.7%.
- Sample Technologies: While a specific global market size for "sample technologies" as a standalone category is not provided, it is a core component of molecular testing and an area where Qiagen is a leader. These technologies are foundational to molecular diagnostics and next-generation sequencing workflows.
- QuantiFERON: This is a key product for detecting latent tuberculosis infection. A specific global market size for QuantiFERON or latent TB testing within the broader molecular diagnostics market was not separately identified.
- Bioinformatics (QIAGEN Digital Insights): While Qiagen has significant offerings in bioinformatics, a distinct global addressable market size specifically for "bioinformatics solutions" for molecular testing or life sciences was not identified in the provided search results.
For QuantiFERON and Bioinformatics, specific addressable market sizes directly corresponding to these individual products/services were not explicitly available in the provided information.
AI Analysis | Feedback
Qiagen (symbol: QGEN) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and existing product strengths:- Launch of New Automated Sample Preparation Instruments: Qiagen plans to introduce three new automated sample preparation instruments between 2025 and 2026. The QIAsymphony Connect, the next generation of its flagship platform, is undergoing a phased launch starting in 2025 with a full commercial release in mid-2026. It is designed for liquid biopsy, oncology, and genomics workflows with enhanced automation and digital connectivity. Additionally, QIAsprint Connect, slated for a 2026 launch, will mark Qiagen's entry into the high-throughput automation market, while QIAmini, also expected in 2026, will offer cost-effective automation for smaller laboratories.
- Expansion in Digital PCR and New Assays: The company is significantly expanding its QIAcuity digital PCR platform, aiming for U.S. regulatory clearance for the QIAcuity-Dx version in 2024 for clinical use, with a BCR-ABL biomarker assay submission planned for 2025. Over 100 new assays are being launched, supported by a more than tripling of sales specialists to drive adoption.
- Acquisition of Parse Biosciences and Entry into the Single-Cell Market: The acquisition of Parse Biosciences, expected to be completed in late 2025, provides Qiagen with entry into the rapidly growing single-cell market. Parse Biosciences offers scalable, instrument-free solutions for single-cell research, which is projected to contribute approximately $40 million in sales to Qiagen in 2026, with strong double-digit growth in subsequent years. This move is also anticipated to accelerate growth in Qiagen Digital Insights (QDI) bioinformatics business.
- Sustained Performance of Core Diagnostic Products: Key existing diagnostic products like QuantiFERON and QIAstat-Dx are expected to maintain strong growth. QuantiFERON is projected for at least 10% constant exchange rate (CER) growth in 2024 and double-digit growth in 2025, driven by global market adoption. QIAstat-Dx has shown dynamic double-digit growth, including a 40% CER pace in Q3 2024, supported by the launch of a new gastrointestinal panel in the U.S.
- Operational Efficiencies and Portfolio Rationalization: While not a direct revenue driver, Qiagen's focus on operational efficiencies and strategic portfolio decisions, such as the discontinuation of the NeuMoDx system by 2025, are contributing to improved profitability and freeing up resources for investment in growth areas. The company aims to improve its adjusted operating income margin by at least 150 basis points to above 30% in 2025 and well above 31% by 2028.
AI Analysis | Feedback
Share Repurchases
- QIAGEN announced a plan to complete a $500 million synthetic share repurchase in early January 2026, which would bring total shareholder returns to over $1 billion since 2024, ahead of its 2028 goal.
- Shareholders approved a resolution in June 2024 to implement a share repurchase of up to $300 million, designed to return cash more efficiently and enhance earnings per share.
Share Issuance
- In August 2025, QIAGEN announced an offering of $750 million in senior, unsecured net share settled convertible bonds due 2032.
- The shares underlying these convertible bonds represent approximately 11.2 million shares, or about 5.1% of the company's current issued and outstanding share capital.
- QIAGEN's shares outstanding increased by 3.08% in 2023 to 0.231 billion from 2022, and then declined by 2.56% in 2024 to 0.225 billion from 2023.
Inbound Investments
- In March 2020, Thermo Fisher Scientific proposed to acquire QIAGEN for €39 per share in cash, valuing the transaction at approximately $11.5 billion, including assumed debt; however, the offer was terminated in August 2020 as it did not meet the required shareholder approval threshold.
- Fivespan Partners, an activist investment firm, acquired a stake in Qiagen in April 2025, potentially indicating strategic discussions aimed at influencing management decisions and increasing shareholder value.
Outbound Investments
- In November 2025, QIAGEN entered into a definitive agreement to acquire Parse Biosciences for an upfront cash payment of approximately $225 million, with potential additional milestone payments of up to $55 million, to expand its Sample technologies portfolio into the single-cell sequencing market.
- QIAGEN announced its intention to acquire Verogen for $150 million in January 2023, which included the acquisition of GEDmatch, a genetic genealogy service.
- In May 2022, QIAGEN acquired a majority stake in BLIRT S.A., enhancing its R&D and manufacturing capabilities for recombinant enzymes and molecular biology reagents.
Capital Expenditures
- QIAGEN focuses its capital expenditures on strategic initiatives to accelerate growth in key areas such as QIAcuity digital PCR (dPCR), QIAstat-Dx syndromic testing, and its QIAGEN Digital Insights (QDI) portfolio.
- Capital expenditures are also directed towards production capacity expansion initiatives, supporting its five pillars of growth.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to QGEN. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Qiagen
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 61.77 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.6% |
| Rev Chg 3Y Avg | 2.2% |
| Rev Chg Q | 8.3% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 20.1% |
| Op Mgn 3Y Avg | 17.8% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 22.2% |
| CFO/Rev 3Y Avg | 23.8% |
| FCF/Rev LTM | 20.1% |
| FCF/Rev 3Y Avg | 19.4% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Diagnostic solutions | 698 | 661 | 639 | 461 | 466 |
| Sample technologies | 663 | 797 | 851 | 804 | 548 |
| Polymerase Chain Reaction (PCR) / Nucleic acid amplification | 300 | 391 | 434 | 364 | 225 |
| Genomics / Next-Generation Sequencing (NGS) | 239 | 225 | 245 | 166 | 184 |
| Other | 66 | 68 | 83 | 77 | 104 |
| Total | 1,965 | 2,142 | 2,252 | 1,870 | 1,526 |
Price Behavior
Price Behavior
| Market Price | $45.37 | |
| Market Cap ($ Bil) | 9.8 | |
| First Trading Date | 06/28/1996 | |
| Distance from 52W High | -12.4% | |
| 50 Days | 200 Days | |
| DMA Price | $46.15 | $45.41 |
| DMA Trend | up | indeterminate |
| Distance from DMA | -1.7% | -0.1% |
| 3M | 1YR | |
| Volatility | 21.6% | 25.6% |
| Downside Capture | 55.64 | 47.53 |
| Upside Capture | 60.07 | 41.32 |
| Correlation (SPY) | 20.5% | 41.0% |
QGEN Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.36 | 0.33 | 0.33 | 0.34 | 0.54 | 0.58 |
| Up Beta | 0.22 | 0.16 | 0.34 | 0.18 | 0.73 | 0.71 |
| Down Beta | -0.94 | 0.03 | -0.07 | 0.02 | 0.45 | 0.36 |
| Up Capture | 81% | 69% | 47% | 45% | 32% | 22% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 11 | 23 | 34 | 69 | 124 | 366 |
| Down Capture | 46% | 36% | 54% | 59% | 50% | 87% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 9 | 19 | 29 | 56 | 122 | 378 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of QGEN With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| QGEN | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 2.1% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.2% |
| Annualized Volatility | 25.4% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | 0.04 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 59.7% | 41.0% | 9.8% | 1.9% | 43.2% | 21.4% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of QGEN With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| QGEN | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -1.8% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 23.5% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.6% |
| Sharpe Ratio | -0.10 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 53.1% | 45.2% | 13.5% | -1.1% | 41.7% | 17.6% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of QGEN With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| QGEN | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 5.7% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 26.4% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.24 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 42.1% | 36.9% | 7.9% | 7.9% | 27.0% | 8.7% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/06/2025 | 6-K (09/30/2025) |
| 06/30/2025 | 08/21/2025 | 6-K (06/30/2025) |
| 03/31/2025 | 05/13/2025 | 6-K (03/31/2025) |
| 12/31/2024 | 03/31/2025 | 20-F (12/31/2024) |
| 09/30/2024 | 11/08/2024 | 6-K (09/30/2024) |
| 06/30/2024 | 08/02/2024 | 6-K (06/30/2024) |
| 03/31/2024 | 05/01/2024 | 6-K (03/31/2024) |
| 12/31/2023 | 03/11/2024 | 20-F (12/31/2023) |
| 09/30/2023 | 11/01/2023 | 6-K (09/30/2023) |
| 06/30/2023 | 08/10/2023 | 6-K (06/30/2023) |
| 03/31/2023 | 05/05/2023 | 6-K (03/31/2023) |
| 12/31/2022 | 03/13/2023 | 20-F (12/31/2022) |
| 09/30/2022 | 11/09/2022 | 6-K (09/30/2022) |
| 06/30/2022 | 07/29/2022 | 6-K (06/30/2022) |
| 03/31/2022 | 04/29/2022 | 6-K (03/31/2022) |
| 12/31/2021 | 03/14/2022 | 20-F (12/31/2021) |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.